[
    [
        {
            "time": "",
            "original_text": "2019全球生物技术公司TOP25：恒瑞、药明康德等5家中国公司上榜！",
            "features": {
                "keywords": [
                    "全球生物技术",
                    "TOP25",
                    "恒瑞",
                    "药明康德",
                    "中国公司"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2019全球生物技术公司TOP25：恒瑞、药明康德等5家中国公司上榜！",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "惠誉给予药明康德长期发行人违约“BBB-”评级",
            "features": {
                "keywords": [
                    "惠誉",
                    "药明康德",
                    "长期发行人违约",
                    "BBB-"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "惠誉给予药明康德长期发行人违约“BBB-”评级",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "标普：给予药明康德“BBB-”评级",
            "features": {
                "keywords": [
                    "标普",
                    "药明康德",
                    "BBB-"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "标普：给予药明康德“BBB-”评级",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]